Patent · US Expired

Nucleic acid constructs containing hybrid promoters

US6576758B1 · kind B1 · utility

3Cited by

7References

17Claims

0Family size

Assignee

Aventis Pharma Deutschland GmbH · DE

Inventors

Klaus-Heinrich Seifart · Marburg, DE
Rolf Mueller · Ingolstadt, DE
Hans-Harald Sedlacek · Marburg, DE

Key dates

Filing date	Sep 24, 1997
Grant date	Jun 10, 2003
Priority date	—
Expiry date	Sep 24, 2017

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Nucleic acid constructs containing hybrid promoters for use in gene therapy and genetic manipulation. The invention relates to a nucleic acid construct for the precise, regulated expression of genes in host cells, which construct exhibits at least one mutation which inhibits the proper expression of the expressed gene and exhibits at least one additional second mutation which relieves the inhibition due to the first mutation, to an isolated cell which harbors the nucleic acid construct, and to the use of the nucleic acid construct for preparing pharmaceuticals and for treating diseases with excessive cell proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.